MedTrace Logo

Safety and Efficacy of Autologous PRP and PPP Eye Drops in the Treatment of Ocular GVHD

NCT02561520 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2017-08-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of autologous Platelet Rich Plasma (PRP) and Platelet Poor Plasma (PPP) eye drops four times a day in the treatment of ocular graft versus host disease (O-GVHD). In addition to their current medication (except autologous serum drops), patients will receive PRP and PPP drops.

Conditions

  • Graft-versus-host Disease

Interventions

BIOLOGICAL

PRP eye drops

Eye drops 4x a day, patients will start this eye drop first.

BIOLOGICAL

PPP eye drops

Eye drops 4x a day, patients will start this eye drops after PRP.

Sponsors & Collaborators

  • Ladan Espandar

    lead OTHER

Principal Investigators

  • Ladan Espandar, MD · University of Pittsburgh

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2018-09-30
Completion
2018-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02561520 on ClinicalTrials.gov